Jiangsu Hengrui Pharmaceuticals (600276.SH): The application for market approval for Insulin Injection (Shudiyindu) has been accepted.

23/01/2025

Hengrui Medicine (600276.SH) announced that recently, the company received a notice from the National Medical Products Administration titled "Received...".

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has recently received a "Notice of Acceptance" from the National Medical Products Administration. The company's application for the market authorization of Category 1 therapeutic biological product Seglitide insulin injection has been accepted by the National Medical Products Administration. This product is the first domestically developed long-acting insulin analog. Seglitide insulin injection is a basic long-acting insulin independently developed by the company, with advantages such as smooth onset of action, long duration of action, and lower risk of nighttime hypoglycemia.

HK Stock Market Move | CHENMING PAPER (01812) falls more than 6%, the company's main production base is shut down for maintenance, and it is expected to turn losses of more than 3.5 billion yuan in the first half of the year.

HK Stock Market Move | Ganfeng Lithium Group (01772) fell more than 4% as the prices of lithium salts and lithium batteries continued to decline. The company still expects to incur a loss of more than 300 million yuan in the first half of the year.

HK Stock Market Move | JINGCHENG MAC(00187) falls more than 7%, expected mid-term net loss to exceed 18 million RMB, pressure on gas storage and transportation sector export business.